← SynDRA
UBROGEPANT
SynDRA canonical compound SYN0037200 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | CALCRL |
|---|
| Mechanism of action | calcitonin antagonist |
|---|
| Indication | migraine headache |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- CALCRL ANTAGONIST
- Calcitonin gene-related peptide type 1 receptor antagonist
- calcitonin antagonist
Drug classes
- Calcitonin Gene-related Peptide Receptor Antagonist
- Calcitonin Gene-related Peptide Receptor Antagonists
ATC classes
- N02C · ANTIMIGRAINE PREPARATIONS
Cross-references
Synonyms
- ubrelvy
- Ubrogepant anhydrous
- MK-1602
- Ubrelvy
- UNII-AD0O8X2QJR
- AD0O8X2QJR
- Ubrogepant [USAN:INN]
- Ubrogepant (USAN/INN)
- SCHEMBL3698428
- CHEMBL2364638
- GTPL10176
- DTXSID00160178
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N
- MK1602
- ZINC95598454
- SB19741
- HY-12366
- CS-0011109
- D10673
- (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
- Ubrogepantum
- RefChem:57097
- DTXCID9082669
- MFCD28386182
- Ubrogepant [USAN]
- Ubrelvy (TN)
- Ubrogepant (Standard)
- UBROGEPANT [MI]
- UBROGEPANT [INN]
- UBROGEPANT [WHO-DD]
- orb1307638
- SCHEMBL29373722
- SCHEMBL30596427
- UBROGEPANT [ORANGE BOOK]
- US9833448, Example 1
- C29H26F3N5O3
- CHEBI:234515
- US10272077, Example 1
Reported adverse events
- Hypersensitivity
- Hypertension
- Nausea
- Somnolence
Look up UBROGEPANT in the interactive SynDRA portal →